Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Accurate Staging and Determining Resectability in NSCLC
Accurate Staging and Determining Resectability in NSCLC
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Unresectable Stage III NSCLC: Highlights From the Oncology Meeting in Chicago 2024
Unresectable Stage III NSCLC: Highlights From the Oncology Meeting in Chicago 2024
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Managing Immune-Related Adverse Events With Immunotherapies
Managing Immune-Related Adverse Events With Immunotherapies